Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine in Autism Spectrum Disorder
NCT02611921Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Dec 2015
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine transdermal patch in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist at Day 35. Started Dec 2015; status: completed.
02
Drugs
ketamine transdermal patch
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02611921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611921.